Pharmaceutical manufacturers of Fenofibrate

We are committed to providing innovative and quality medicines to the nearly 200 million people we serve around the world every day; we make contact with patients, families and communities for better health and better days.

Headquartered in Mumbai, India, Lupin is a global pharmaceutical leader with a footprint across the U.S., LATAM, APAC, EMEA and India, with products distributed in over 100 markets. With a diverse portfolio of over 1,200 products, Lupin remains committed to its mission of making quality healthcare accessible to the communities we serve. Our visionary Founder, Dr. Desh Bandhu Gupta, instilled in us the importance of offering quality, affordable and innovative medicines and being a responsible corporate citizen, making a positive difference to patients, communities and the environment.

Unichem Laboratories was founded in 1944 by Late Mr. Amrut Mody, a pioneer in the Indian pharmaceuticals business. With a rich tradition of unwavering quality and reliability, Unichem brings together a unique blend of modern, value-added research and deep knowledge of the Indian pharmaceuticals industry.ç

Jiangsu Nhwa Pharmaceutical Co., Ltd. was initially founded in 1978. In year 2008, Nhwa listed on the Shenzhen stock exchange with the stock code 002262. NHWA Pharma integrates R&D, production and sales together, as national psychiatric drugs designated unit, national high-tech enterprise, China’s top 100 pharmaceutical enterprises, national intellectual property rights demonstration unit, national "20 years 20 star" medical quality management enterprise star unit, international environmental certification (ISO14000) confirmed enterprise, the first batch of innovative enterprises in Jiangsu province, and vice President unit of China narcotic drug association.

Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Headquartered in Vadodara, Gujarat, we derive a third of our revenue of over $600 million from the India market.

Moehs Ibérica is the headquarters of the MOEHS Group. Moehs Ibérica currently has 138 employees in the following departments: Accounting/Treasury, Purchasing/Logistics, Sales/Marketing, Human Resources, IT, Quality Assurance/Regulatory Affairs, Research and Intellectual Property. It provides services to the entire group and each of its subsidiaries. In addition, it has its own R&D building with all its services and a plant dedicated to the production of small quantities of ingredients for the pharmaceutical industry, as well as a plant for the manufacture of High Potency Active Ingredients.

Since our inception in 2006, Titan Laboratories has focused on formulating new-age solutions in diversified spectrums of Pellets, Granules, Tablets and Capsule manufacturing. With the expertise of such widespread specialties, we at Titan Laboratories take great pride in our proficiency in providing Quality Analytical Services that focus on the formulation & packaging of both solid and semi-solid finished products. Backed by our holistic approach towards catering to multifarious integrated services, we aim to meet the concept-to-commercialization needs of our customers while providing quality pellets, granules or finish formulations.

We are one of world’s leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector. We endeavour to serve patients by moulding science and technology into therapies to improve health outcomes and people’s lives.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

For more than three decades, we have been providing support to the pharmaceutical and biopharmaceutical sectors in the development of medications. Our aim is to aid our clients in the creation and introduction of new drugs to the market, ultimately enhancing the well-being of patients globally. We are dedicated to assisting our partners in producing and manufacturing intricate and demanding compounds, highly active ingredients, and pioneering advancements in vitamin, healthcare, and industrial products with the goal of making the world a better place.

From removing the regular pain of fingersticks as people manage their diabetes to connecting patients to doctors with real-time information monitoring their hearts, from easing chronic pain and movement disorders to testing half the world’s blood donations to ensure a healthy supply, our purpose is to make the world a better place by bringing life-changing health technologies to the people who need them. That’s our commitment to helping you live your best life.

Harman Finochem Limited is an India-based Pharmaceutical Company catering to its clients across the globe. Established by Mr. Bhupinder Singh Manhas in 1983, our core competencies are in manufacturing and exporting of Active Pharmaceutical Ingredients mainly Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, Glycopyrrolate/Glycopyrronium bromide and more.

Ami Lifesciences, established in 2006, is one of the fastest growing Active Pharmaceutical Ingredient (API) manufacturing companies in India, meeting unmet patient needs in various therapeutic areas such as Cardiovascular, Anti-Diabetics, CNS, and Respiratory amongst other categories, produced From Manufacturing unit located in Vadodara, Gujarat. We are recognised as a reliable supplier of generic APIs and a trustworthy Contract Development & Manufacturing partner for generic, Big Pharma & innovator pharmaceutical companies worldwide. We are among the leading manufacturers of APIs, intermediates and registered Key Starting Materials offering quality products with highest quality compliance & integrity to over 60+ countries. We believe, unlocking early launch opportunities, being cost competitive by virtue of backward integration and offering complete supply chain assurance is key to enable our customers to succeed & sustain their products through the product life cycle over a period of time.

COSMA S. P. A. (established in 1977) and AMSA S. P. A. (established in 1953) are a pair of chemical facilities widely recognized globally and particularly valued in the occidental world and in the nations that adhere to the Pharmaceutical Inspection Convention (PIC). They are part of the CFM Group, a privately-owned company engaged in the fields of chemistry and pharmaceuticals since 1949

Zim offers innovative solutions for administering medications, focusing on enhancing patient convenience and compliance. The company utilizes its own advanced technologies, such as modified release and taste masking, to create and produce distinct pharmaceutical products. Their range includes oral solid dosage formulations and pre-formulations (PFI), encompassing tablets, capsules, dry syrups, pellets, granules, and orally disintegrating strips (ODS). Additionally, they provide services for site transfer/variation for sustained release tablets, oral disintegrating tablets, fast disintegrating capsules, and more.

Axyntis Group, established in 2007, is the foremost independent multi-location entity in the field of fine chemicals in France, generating an annual revenue of €90 million. Axyntis has evolved into a significant manufacturer of APIs in France through acquisitions and collaborations. It encompasses two sectors (colorants and fine chemicals) and emphasizes diversification and pioneering initiatives. The company operates three cGMP facilities in France, two of which are approved by the FDA. It offers CDMO services to partners for their API or advanced intermediate projects, from the initial development phase to the commercial stage, inclusive of preparative chromatography (Kyrapharm subsidiary). Additionally, it markets exclusive APIs.